Relationship between circulating tumor necrosis factor system and bone mass before and after estrogen plus progestogen therapy

Objective: The aim of his study was to investigate the relationship between the circulating tumor necrosis factor (TNF) system and bone mineral density (BMD) before and after estrogen plus progestogen therapy (EPT). Methods: Serum levels of TNF-alpha, TNF-beta, soluble TNF receptor (sTNFR) 1, sTNFR2, and bone turnover markers and BMDs at the lumbar spine and proximal femur were measured in 192 postmenopausal Korean women. Among all women, 70 were treated with sequential EPT for 1 year. Results: BMDs at all skeletal sites and bone turnover markers were not correlated with serum TNF and sTNFR. After adjustment for age, years since menopause, and body mass index, serum TNF-beta levels were significantly lower in osteoporotic women than in normal women, whereas serum levels of TNF-alpha and sTNFR did not differ among normal, osteopenic, and osteoporotic postmenopausal women. After 6 months of EPT, serum TNF-beta levels increased significantly (P < 0.05), whereas serum TNF-alpha, sTNFR1, and sTNFR2 levels were unchanged. The 1-year changes in BMD at the lumbar spine and proximal femur after EPT were not correlated with the basal levels of serum TNF-alpha and sTNFR and their changes 6 months after EPT. Conclusions: In the circulating TNF system, only serum TNF-beta levels were lower in osteoporotic postmenopausal women compared with normal postmenopausal women and increased after EPT, but changes in circulating TNF and sTNFR after EPT had no association with changes in bone markers and BMD. The circulating TNF system may not be clinically useful for predicting BMD and bone response after EPT.Ding C, 2008, J CLIN ENDOCR METAB, V93, P1952, DOI 10.1210/jc.2007-2325Somunkiran A, 2008, GYNECOL ENDOCRINOL, V24, P79, DOI 10.1080/09513590701718307Ozmen B, 2007, EUR CYTOKINE NETW, V18, P148Zegura B, 2006, MENOPAUSE, V13, P643, DOI 10.1097/01.gme.0000198485.70703.7aGonzalez-Calvin JL, 2004, J CLIN ENDOCR METAB, V89, P4325, DOI 10.1210/jc.2004-0077Tikiz C, 2004, J BONE MINER METAB, V22, P365, DOI 10.1007/s00774-004-0496-0Gur A, 2002, RHEUMATOL INT, V22, P194, DOI 10.1007/s00296-002-0223-xPantsulaia I, 2002, CYTOKINE, V19, P138, DOI 10.1006/cyto.2002.1959SAHIN G, 2002, SINGAP MED J, V43, P576Walsh BW, 2001, AM J CARDIOL, V88, P825Ito A, 2001, J IMMUNOL, V167, P542Rogers A, 2001, BONE, V29, P30Deswal A, 2001, CIRCULATION, V103, P2055Kamada M, 2001, AM J OBSTET GYNECOL, V184, P309Porter VR, 2001, EXP GERONTOL, V36, P3112000, NIH CONSENSUS STATEM, V17, P1Salamone LL, 1998, CALCIFIED TISSUE INT, V63, P466Zheng SX, 1997, MATURITAS, V26, P63ADERKA D, 1996, CYTOKINE GROWTH F R, V7, P231KANIS JA, 1994, J BONE MINER RES, V9, P1137DIRENZO GC, 1994, EUR J OBSTET GYN R B, V56, P47VANDERPLUIJM G, 1991, ENDOCRINOLOGY, V129, P1596RALSTON SH, 1990, J BONE MINER RES, V5, P983THOMSON BM, 1987, J IMMUNOL, V138, P775